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Summary  In  industrialized  countries,  chronic  heart  failure  (HF)  is  a  major  illness  and  cause
of death.  However,  because  of  the  paucity  of  speciﬁc  clinical  manifestations  of  HF,  its  early
diagnosis and  management  might  be  challenging.  Therefore,  biochemical  markers  of  HF  arepeptide;
Cardiac  troponin;
Neurohormone;
Renin—angiotensin—
now being  closely  scrutinized.  An  ideal  biochemical  marker  should  be  a  prognostic  indicator,
should assist  in  the  early  diagnosis,  reﬂect  the  therapeutic  response,  and  help  grading  the
risk associated  with  each  stage  of  HF.  This  review  summarizes  our  current  understanding  of
biochemical  markers  of  HF.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.aldosterone;
Cytokine
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Table  1  Prognostic  biochemical  markers  in  patients
with chronic  congestive  heart  failure  based  on  its
pathophysiology.
1.  Neurohormones
2. Tissue  markers
Markers  of  myocyte  injury:  troponin
Markers  of  collagen  deposition:  procollagen  type  III
aminoterminal  peptide
3.  Markers  of  metabolic  abnormalities:  hemoglobin,
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hronic  heart  failure  (HF)  is  a  major  illness  and  cause  of
eath  in  the  aged.  While  the  emphasis  of  its  management
s  shifting  toward  early  interventions  and  preservation  of
uality  of  life,  as  well  as  lowering  mortality  [1,2], the
aucity  of  speciﬁc  clinical  manifestations  hampers  the  diag-
osis  and  treatment  of  patients  presenting  in  the  early  stage
f  chronic  HF.  Physical  examination  and  several  laboratory
ests,  including  echocardiogram,  radionuclide  imaging,  car-
iopulmonary  exercise,  and  hemodynamic  measurements,
ontribute  to  grading  the  severity  of  chronic  HF.  However,
ecause  most  signs  are  non-speciﬁc,  this  process  requires
dvanced  procedural  and  interpretative  skills  that  are  often
navailable  to  non-cardiologists.
Biomarkers  are  substances  derived  from  organs,  which
an  be  measured  and  evaluated  as  indicators  of  normal  biol-
gy,  pathogenic  process,  or  pharmacological  response  to  a
herapeutic  intervention.  Their  measurement  is  not  subject
o  inter-observer  variability.  An  ideal  biochemical  marker
hould  be  a  prognostic  indicator,  should  assist  in  the  early
iagnosis  of  HF,  reliably  reﬂect  the  therapeutic  response,
nd  help  in  grading  the  risk  associated  with  each  stage  of
F.  While  several  biochemical  markers  have  been  studied
or  their  prognostic  value  in  the  setting  of  chronic  HF,  their
linical  applications  have  not  been  systematically  discussed.
his  review  summarizes  our  understanding  of  biochemical
arkers  as  they  currently  apply  to  chronic  HF.
rognostic biochemical markers
he  various  biomarkers  that  have  been  studied  for  their
otential  prognostic  value  are  listed  in  Table  1.
eurohormones
orepinephrine
 complex  series  of  neuro-hormonal  changes  take  place  in
esponse  to  a  low  cardiac  output  and  small  arterial  volume
hat  are  characteristic  of  HF  due  to  systolic  left  ventricular
LV)  dysfunction.  Sympathetic  nervous  activity  is  increased,
yocardial  noradrenalin  stores  are  depleted  and  the  beta1-
drenoreceptors  are  downregulated  and  desensitized.  An
nitial  increase  in  adrenergic  activity  might  help  maintain
he  cardiac  performance  in  the  short  term,  with  several
egative  consequences,  including  increased  myocardial  con-
ractility,  tachycardia,  and  arterial  vasoconstriction,  which
ncreases  cardiac  afterload.  The  increase  in  concentrations
f  circulating  norepinephrine  is  due  to  its  increased  release
rom  adrenergic  nerve  endings  and  its  spillover  into  the
lasma,  combined  with  a  reduced  uptake  by  the  nerve
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pcholesterol,  uric  acid,  creatinine,  sodium
4. Markers  of  oxidative  stress
ndings,  while  only  a  small  amount  of  circulating  nore-
inephrine  originates  from  the  heart  [3].
In  the  Vasodilator-Heart  Failure  II  Trial,  which  exam-
ned  several  potential  predictors  of  outcome  in  nearly  750
atients,  including  baseline  LV  ejection  fraction  (EF),  peak
xygen  consumption  during  exercise,  and  cardiothoracic
atio,  log  plasma  norepinephrine  remained  the  only  inde-
endent  predictor  of  mortality  [4].  The  Cooperative  North
candinavian  Enalapril  Survival  Study  found  a positive  cor-
elation  between  mortality  and  plasma  norepinephrine  in
he  group  of  patients  assigned  to  placebo  [5].  In  the  Studies
f  Left  Ventricular  Dysfunction,  the  median  plasma  nore-
inephrine  concentration  was  signiﬁcantly  higher  in  patients
ith  LV  dysfunction  than  in  normal  controls  [6].  While  these
istorical  observations  are  robust,  the  need  for  bed  rest
efore  blood  sampling,  and  for  high-performance  liquid
hromatography,  a  time-consuming  procedure  that  is  not
eadily  available,  has  limited  the  clinical  use  of  plasma  nore-
inephrine  concentrations.
enin,  angiotensin,  aldosterone
he  activity  of  the  circulatory  renin—angiotensin—
ldosterone  system  is  central  to  the  maintenance  of
ater  and  electrolyte  balance  and  blood  volume,  and  the
ocal  renin—angiotensin  system  plays  an  important  role
n  the  pathogenesis  of  chronic  HF  [3].  Renin  is  mainly
eleased  by  the  juxta-glomerular  cells  in  response  to  renal
ypoperfusion  and  sympathetic  activation.  Angiotensinogen
s  cleaved  by  renin  to  form  angiotensin  I,  which  is  con-
erted  by  the  angiotensin-converting  enzyme  (ACE)  into
ngiotensin  II,  a  stimulator  of  aldosterone  production  by
he  adrenal  cortex.  However,  in  patients  suffering  from
hronic  HF,  these  compensatory  mechanisms  ultimately
ncrease  the  pre  and  afterload.  While  patients  with  mild
hronic  HF  may  have  little  or  no  increase  in  plasma  renin  or
lasma  aldosterone  concentrations,  their  activation  does
redict  outcome,  although  perhaps  not  as  accurately  as
lasma  norepinephrine  [4,5].
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Cytokines
Besides  the  activation  of  sympathetic  activity  and  the
renin—angiotensin—aldosterone  system,  immunologic  and
inﬂammatory  processes  have  recently  been  implicated  in
the  pathogenesis  of  chronic  HF  [7].  The  concentrations  of
circulating  cytokines  that  have  negative  inotropic  effects
on  the  heart,  such  as  tumor  necrosis  factor-alpha  (TNF-)
and  interleukin  (IL)-6,  are  increased  and  have  been  associ-
ated  with  an  unfavorable  prognosis  in  patients  with  chronic
HF.  In  a  study  of  >150  patients  presenting  with  chronic  HF,
increases  in  total  and  trimeric  TNF-, soluble  TNF  receptor
(sTNF-R)1,  sTNF-R2,  and  IL-6  predicted  the  24-month  mor-
tality  [8].  By  multiple  variable  analysis,  sTNF-R1  emerged
as  the  strongest  prognostic  factor,  independent  of  New  York
Heart  Association  (NYHA)  functional  class  and  LVEF.  Like-
wise,  in  the  Vesnarinone  Trial,  which  enrolled  patients  with
chronic  HF,  TNF,  IL-6,  sTNF-R1,  and  sTNF-R2  were  inde-
pendent  predictors  of  mortality  [9].  Serum  ST2,  a  member
of  the  IL-1  receptor  family,  was  measured  in  161  patients
enrolled  in  the  Protective  Randomized  Amlodipine  Survival
Evaluation-2  Trial  [10]. By  multiple  variable  analysis,  the
changes  in  ST2,  which  occurred  between  baseline  and  2
weeks  later,  predicted  mortality,  independently  of  brain
natriuretic  peptide  (BNP)  and  pro-atrial  natriuretic  peptide
(ANP).
C-reactive  protein  (CRP)  is  a  product  of  inﬂammation  syn-
thesized  in  the  liver,  stimulated  mainly  by  IL-6.  In  over  4200
patients  enrolled  in  the  Valsartan  Heart  Failure  Trial  (Val-
HeFT),  CRP  and  BNP  were  independently  related  to  mortality
and  morbidity  [11]. At  1  year,  treatment  with  valsartan  was
associated  with  a  decrease  in  CRP  among  patients  who  were
not  treated  with  an  ACE  inhibitor.  The  authors  hypothesized
that  LV  dysfunction,  hepatic  or  renal  organ  injury  induced  by
a  low  cardiac  output,  hypoperfusion,  hypoxia,  and  venous
congestion  may  all  be  sources  of  increased  IL-6  and  CRP
production.
Low  plasma  concentrations  of  adiponectin,  an  adipocyte-
speciﬁc  cytokine,  have  been  linked  to  an  increased  risk
of  adverse  cardiovascular  events  in  apparently  healthy
individuals  [12]. On  the  other  hand,  a  high  adiponectin
concentration  predicted  mortality  independently  of  NT-
proBNP  in  195  patients  suffering  from  chronic  HF  [13].
Since  weight  loss  was  associated  with  an  increase  in  plasma
adiponectin  concentrations  [14], a  high  plasma  adiponectin
is  a  suspected  marker  of  physical  wasting,  explaining  the
association  observed  between  high  adiponectin  concentra-
tions  and  increased  risk  of  death  in  patients  with  chronic  HF.
Natriuretic  peptide
In  contrast  to  other  neurohormones  that  are  elevated  in
chronic  HF,  ANP  and  BNP  seem  to  play  adaptive  counter-
regulatory  roles  [15]. Both  hormones  are  synthesized  as
amino  acid  precursor  proteins.  Pro-ANP  is  sequestered  in
atrial  storage  granules,  and  cleaved  into  N-terminal  proANP
and  active  hormone  ANP  upon  its  release  into  the  circu-
lation.  BNP  is  regulated  during  gene  expression,  and  is
released  from  ventricular  myocytes  as  N-terminal  proBNP
(NT-proBNP)  and  BNP,  the  active  hormone.  ANP  and  BNP,
which  seem  to  produce  identical  effects,  relax  vascular
smooth  muscle,  dilate  arteries  and  veins,  lower  blood
pressure  and  ventricular  preload,  and  inhibit  sympathetic
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ctivity  and  the  renin—angiotensin—aldosterone  system.
hey  also  increase  glomerular  ﬁltration  and  inhibit  sodium
eabsorption  by  the  kidney,  promoting  natriuresis  and  diure-
is.  BNP  is  more  reliable  than  ANP  or  N-terminal  proANP
n  the  evaluation  of  chronic  HF  and  plasma  concentrations
f  BNP  are  currently  used  as  diagnostic  and  prognostic
arkers  in  patients  with  chronic  HF  [16]. It  is  particularly
oteworthy  that,  by  multiple  variable  analysis,  BNP  was  a
tronger  predictor  of  mortality  than  NHYA  functional  class,
NP,  norepinephrine,  LVEF,  or  age  [17]. In  Val-HeFT,  nore-
inephrine,  BNP,  aldosterone,  plasma  renin  activity  (PRA),
ig  endothelin  (ET)-1,  and  ET-1  were  assayed  at  baseline
n  4300  patients.  By  multiple  variable  analysis,  BNP  was
ost  closely  correlated  with  mortality,  followed  by  nore-
inephrine  and  PRA  [18]. BNP  is  also  a  predictor  of  survival
n  patients  with  acutely  decompensated  HF.  In  the  Acute
ecompensated  Heart  Failure  Registry,  the  relation  between
NP  concentration  on  admission  to  the  hospital  and  in-
ospital  mortality  was  linear  [19].
NT-proBNP:  (a)  has  a  longer  half-life  than  BNP,  (b)  is  sta-
le  in  whole  blood,  and  is  elevated  in  patients  with  chronic
F.  A  substudy  of  the  Carvedilol  Prospective  Randomized
umulative  Survival  (COPERNICUS)  examined  the  prognostic
alue  of  NT-proBNP  in  a  large  population  of  patients  present-
ng  with  severe  chronic  HF  [20]. The  laboratory  medicine
ractice  guidelines  formulated  by  the  National  Academy
f  Clinical  Biochemistry  (NACB)  state  that  ‘‘Blood  BNP  or
T-proBNP  testing  can  provide  a  useful  addition  to  clinical
ssessment  in  selected  situations  when  additional  risk  strat-
ﬁcation  is  required’’  and  assigned  it  a  class  IIa,  evidence
evel  A  [16].
ndothelin-1
T is  a  potent  vasoconstrictor  peptide  that  has  long-term
ffects  on  cellular  growth  and  phenotype.  It  is  synthesized
n  the  vasculature  and  myocardium  by  various  cell  types,
ncluding  vascular  endothelial  cells,  ventricular  myocytes,
nd  ﬁbroblasts.  Stimulation  of  ET-A  receptors  on  vascu-
ar  smooth-muscle  cells  causes  vasoconstriction.  In  vitro,
t  stimulates  myocyte  hypertrophy  and  the  expression  of  a
etal  phenotype.  It  also  has  prominent  effects  on  the  synthe-
is  and  degradation  of  the  extracellular  matrix.  High  plasma
oncentrations  of  ET-1  and  of  its  precursor,  big  ET-1,  are
redictive  of  outcome  in  chronic  HF  [18].
issue  markers
arkers  of  myocyte  injury
athologic  changes  occurring  in  cardiac  myocytes  are  an
mportant  cause  of  cardiac  remodeling  [21]. For  instance,
poptosis  may  be  closely  involved  in  the  response  to  pressure
verload.  In  addition,  some  biochemical  markers  described
arlier  might  contribute  to  myocyte  injury.  Norepinephrine,
n  concentrations  found  in  the  failing  heart,  is  cardiotoxic
nd  causes  necrosis  of  the  myocytes.  Angiotensin  II,  a  prod-
ct  of  the  renin—angiotensin  system,  induces  necrosis  and
poptosis  of  neonatal  and  adult  ventricular  myocytes.  Like-
ise,  TNF- causes  the  apoptosis  of  the  myocytes.  These
omplex  mechanisms  of  myocyte  necrosis  and  apoptosis,
nduced  by  stretch,  ongoing  ischemia  and  neuro-hormonal
hanges  have  been  reviewed  in  detail  elsewhere  [22].
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Biochemical  markers  originating  from  cellular  con-
tituents  are  useful  to  estimate  the  severity  of  myocyte
njury,  and  were  initially  developed  to  diagnose  acute
yocardial  infarction  (AMI).  The  3-unit  troponin  I,  T,  and
 complex  located  on  the  actin  ﬁlament  is  essential,  with
ropomyosin,  for  the  regulation  of  calcium-mediated  con-
raction  of  the  skeletal  and  cardiac  muscles.  The  highly
ensitive  and  speciﬁc  markers  of  myocardial  injury,  serum
ardiac  troponin  (cTn)  T  and  I,  have  replaced  the  MB  frac-
ion  of  creatine  kinase  as  the  gold  standard  for  the  diagnosis
f  AMI  [23].
Despite  being  generally  lower  than  those  measured  dur-
ng  AMI,  the  concentrations  of  both  cTnT  and  cTnI  are
rognostic  indicators  in  patients  suffering  from  chronic  HF,
hether  of  ischemic  or  of  non-ischemic  etiology  [24,25]. It
s  noteworthy  that  persistently  increased  concentrations  of
TnT,  including  during  compensated  phases  of  the  syndrome,
ave  been  measured  during  ongoing  cardiac  remodeling  and
n  patients  whose  prognosis  is  poor  [24,26],  which  suggests
hat  it  is  a  marker  of  ongoing  myocyte  injury  taking  place
uring  the  remodeling  process.
Although  the  medical  practice  guidelines  formulated  by
rofessional  organizations  suggest  to  use  the  99th  percentile
f  a  healthy  reference  population  with  a  ≤10%  coefﬁcient  of
ariance,  as  the  upper  limit  of  normal  values  for  the  diag-
osis  of  AMI  [23], the  majority  of  cTnT  and  cTnI  assays  at
he  99th  percentile  were  not  accurate  enough.  However,
he  high-sensitivity  (Hs)  assay  developed  recently  is  able  to
easure  low  concentrations  of  cTn  with  high  precision.  In
ver  4000  patients  enrolled  in  Val-HeFT,  cTnT  concentra-
ions  ≤0.01  ng/ml  (median  =  0.027  ng/ml)  were  detectable
n  10.4%  of  patients  with  the  conventional  assay,  compared
ith  concentrations  ≤0.001  ng/ml  (median  =  0.012  ng/ml)  in
2.0%  of  patients  with  the  hs-cTnT  assay  [27]. In  contrast
o  the  report  of  the  results  of  conventional  cTnT  assay  as
 positive  or  negative  categorical  variable,  the  prognosis
f  patients  presenting  with  chronic  HF  estimated  by  mea-
urements  made  with  the  hs-cTnT  assay  was  reported  as  a
ontinuous  variable.  It  is  noteworthy  that  when  the  hazard
atio  (HR)  was  plotted  in  deciles  of  hs-TnT,  the  risk  of  death
ncreased  progressively.
The  laboratory  medicine  practice  guidelines  published
y  NACB  state  that  ‘‘Cardiac  troponin  testing  can  identify
atients  with  heart  failure  at  increased  risk  beyond  the  set-
ing  of  acute  coronary  syndromes’’  as  class  IIb  [16].
arkers  of  collagen  deposition
rocesses  involved  in  cardiac  remodeling  other  than
yocyte  injury,  such  as  the  turnover  of  interstitium,
broblasts,  and  collagen,  play  an  important  role  [21]. Nore-
inephrine  and  angiotensin  II  stimulate  the  production  of
ollagen  in  vitro. The  prognostic  value  of  the  serum  con-
entrations  of  procollagen  type  III  amino-terminal  peptide
as  conﬁrmed  in  a  sample  of  over  260  patients  with  chronic
F  enrolled  in  the  Randomized  Aldactone  Evaluation  Study
28].arkers  of  metabolic  abnormalities
nexpensive  markers  are  also  needed,  which  can  be  used
linically.  For  example,  anemia  is  common  in  patients  with
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hronic  HF.  In  over  3000  patients  with  chronic  HF  recruited
n  the  evaluation  of  Losartan  in  the  Elderly-II  trial,  ane-
ia,  NYHA  functional  class,  serum  creatinine  and  LVEF  were
ndependent  predictors  of  death  [29]. In  Val-HeFT,  a  change
n  hemoglobin  concentration  during  12  months  of  observa-
ion  was  inversely  correlated  with  subsequent  mortality  and
orbidity  and,  by  multiple  variable  analysis,  anemia,  BNP,
YHA  functional  class,  uric  acid,  and  PRA  were  indepen-
ent  predictors  of  death  in  >5000  patients  with  chronic  HF
30].
Progressive  worsening  of  chronic  HF  associated  with  renal
nsufﬁciency  is  known  as  the  ‘‘cardio-renal  syndrome’’.
arge  clinical  studies  have  shown  recently  that  even  mild
enal  insufﬁciency  predicts  mortality  independently  of  car-
iac  function  [31]. Cystatin  C  is  a  reliable  means  of  detecting
 mildly  decreased  renal  function,  and  its  measurement  has
een  found  superior  to  measurements  of  glomerular  ﬁltra-
ion  rate  in  the  early  risk  stratiﬁcation  of  patients  presenting
ith  acute  HF  [32].
Serum  sodium  can  also  be  used  as  a  prognostic  indicator.
n  the  Outcomes  of  a  Prospective  Trial  of  Intravenous  Milri-
one  for  Exacerbations  of  Chronic  Heart  Failure  Study,  a  low
erum  sodium  concentration  upon  admission  to  the  hospital
as  an  independent  predictor  of  prolonged  hospitalization
or  cardiovascular  causes  and  of  a  high  mortality  within  60
ays  after  discharge  from  the  hospital  [33]. In  contrast  to
ypercholesterolemia  as  a  predictor  of  death  in  patients
uffering  from  coronary  artery  disease,  a  low  serum  total
holesterol  has  been  associated  with  a  marked  increase  in
ortality  in  patients  presenting  with  advanced  HF.  Rauch-
aus  et  al.  reported  that,  in  patients  with  CHF,  the  chance
f  survival  increased  by  25%  for  each  mmol/l  increment  in
otal  cholesterol,  independently  of  the  etiology  of  HF,  age,
VEF,  and  exercise  capacity  [34].
xidative  stress
xidative  stress  is  increased  systemically  and  in  the
yocardium  of  patients  with  CHF,  either  because  of  a
educed  antioxidant  capacity  or  because  of  an  increased
roduction  of  reactive  oxygen  species.  In  vitro, the  overpro-
uction  of  free  radicals  or  an  impaired  antioxidant  function
epresses  myocardial  contractility,  causes  myocardial  tissue
njury,  and  induces  myocyte  apoptosis.  Since  it  is  difﬁcult
o  measure  free  radicals  directly  in  humans,  indirect  mark-
rs  of  their  activity  have  been  studied.  The  concentrations
f  oxidized  low-density  lipoprotein  (oxLDL)  were  signiﬁ-
antly  higher  in  the  coronary  sinus  than  in  the  aortic  root  of
atients  with  dilated  cardiomyopathy,  suggesting  that  some
f  the  increase  in  oxLDL  is  of  myocardial  origin  and,  in  84
atients  with  CHF,  BNP  and  oxLDL  were  both  independent
redictors  of  mortality  [35].
Besides  being  a  general  marker  of  cell  death,  the  blood
oncentration  of  uric  acid  may  reﬂect  the  degree  of  cir-
ulating  xanthine  oxidase  activity,  an  important  source  of
xygen  free  radicals  that  might  contribute  to  the  progression
f  LV  dysfunction  by  interfering  with  myocardial  energetics.
nker  et  al.  reported  that  elevated  blood  concentrations
f  uric  acid  predicted  mortality  in  112  patients  with  CHF
nd,  by  multiple  variable  analysis,  LVEF  and  uric  acid  were
ndependent  predictors  of  mortality  [36].
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eBiochemical  markers  in  heart  failure  
Diagnostic biochemical markers
Instead  of  prognostic,  BNP  and  NT-proBNP  are  mostly  used
as  diagnostic  biomarkers.  The  contributions  of  blood  BNP
or  NT-proBNP  measurements  in  the  initial  evaluation  of
patients  presenting  with  acute  HF  have  been  conﬁrmed.
In  the  multicenter  Breathing-Not-Properly  Study,  the  use  of
a  100  pg/ml  BNP  concentration  as  a  diagnostic  ‘‘cut-off’’,
identiﬁed  HF  as  the  cause  of  acute  dyspnea  with  a  90%
sensitivity,  76%  speciﬁcity,  and  an  81%  diagnostic  accuracy,
in  1586  patients  presenting  to  the  emergency  department,
which  was  superior  to  a  clinical  assessment  alone  [37].
The  similar  contributions  made  by  the  measurements  of
NT-proBNP  were  conﬁrmed  in  the  ProBNP  Investigation  of
Dyspnea  in  the  Emergency  Department,  in  600  patients
presenting  with  acute  dyspnea.  NT-proBNP  concentrations
>450  pg/ml  at  <50  years  of  age,  and  >900  pg/ml  at  ≥50  years
of  age,  were  highly  sensitive  and  speciﬁc  for  the  diagnosis
of  acute  HF,  while  <300  pg/ml  was  optimal  to  exclude  HF,
with  a  negative  predictive  value  of  99%  [38]. From  these
observations,  the  NACB  laboratory  medicine  practice  guide-
lines  stated  that  ‘‘the  use  of  BNP  or  NT-proBNP  testing  in
an  acute  setting  to  rule  out  or  to  conﬁrm  the  diagnosis
of  heart  failure  among  patients  with  ambiguous  signs  and
symptoms’’,  and  was  assigned  a  class  I,  level  of  evidence  A
[16].
Therapeutic biochemical markers
The  most  robust  endpoint  in  the  study  of  CHF  is  death.
However,  surrogate  endpoints  can  help  in  the  objective
identiﬁcation  of  effective  treatment  strategies.  The  rela-
tionship  between  biochemical  markers  and  therapy  of  CHF
is  key  from  a  clinical  perspective,  and  variations  in  surro-
gate  markers  are  expected  to  be  associated  with  variations
in  the  incidence  of  morbid  events  [39]. In  Moxonidine  for
Congestive  Heart  Failure,  a  study  of  sustained-release  mox-
onidine  on  mortality  and  morbidity  in  patients  suffering  from
chronic  HF,  a  signiﬁcant  increase  in  mortality  associated
with  a  decrease  in  plasma  norepinephrine  was  observed  with
active  treatment  [40]. The  discrepancy  between  change
of  biomarker  and  change  of  mortality  indicates  that  nore-
pinephrine  is  not  a  desirable  surrogate  marker  of  the
response  to  therapy  for  chronic  HF.
In  contrast,  BNP  was  measured  at  baseline  and  at  4,  12,
and  24  months  after  the  random  assignment  of  nearly  4300
patients  to  valsartan  versus  placebo  in  Val-HeFT.  Plasma  BNP
was  an  important  predictor  of  mortality  and  ﬁrst  morbid
event  in  chronic  HF,  and  changes  in  BNP  over  time  were
associated  with  corresponding  changes  in  mortality  and  mor-
bidity  [41]. This  supports  the  hypothesis  that  changes  in  BNP
might  be  a  useful  surrogate  for  adverse  clinical  events.  The
response  of  BNP  and  NT-proBNP  to  therapeutic  interventions
was  also  tested  in  large  clinical  trials.  In  COPERNICUS,  NT-
proBNP  decreased  during  follow-up  in  the  group  of  patients
treated  with  carvedilol  [42]. In  Val-HeFT,  BNP  and  nore-
pinephrine  rose  during  the  study  in  the  group  assigned  to
placebo,  whereas  valsartan  caused  a  sustained  decrease  in
BNP  and  attenuated  the  increase  in  norepinephrine  [43].
Recently,  the  results  of  natriuretic  peptide  guided  ther-
apy  have  been  reported.  In  the  Trial  of  Intensiﬁed  vs.
r
o
d
[5
tandard  Medical  Therapy  in  Elderly  Patients  With  Conges-
ive  Heart  Failure,  the  treatment  of  HF  guided  by  NT-proBNP
as  associated  with  better  outcomes  than  conventional
herapy  in  patients  between  the  ages  of  60  and  75  years,
lthough  not  in  patients  ≥75  years  of  age  [44]. However,
ecause  these  favorable  results  were  not  found  in  other  tri-
ls,  the  merits  of  HF  management  guided  by  BNP  remain
nconﬁrmed  [16]. Moreover,  several  studies  have  shown
ntra-individual  variations  in  the  concentrations  of  BNP,  in
ormal  individuals  as  well  as  in  patients  presenting  with
eemingly  stable  HF.  The  NACB  laboratory  medicine  practice
uidelines  concluded  that  ‘‘routine  blood  BNP  or  NT-proBNP
esting  is  not  warranted  for  making  speciﬁc  therapeutic
ecisions  for  patients  with  acute  or  chronic  heart  failure
ecause  of  the  still  emerging  but  incomplete  data  as  well  as
ntra-  and  inter-individual  variations’’  [16]. Measurements
f  blood  cTn  concentrations  on  admission  to  the  hospital  and
uring  follow-up,  on  the  other  hand,  seem  to  be  a  promising
arker  of  long-term  clinical  outcomes.
In  Val-HeFT,  hs-cTnT  measured  at  baseline  and  at  4
onths  of  follow-up  was  independently  correlated  with  mor-
ality,  suggesting  that  serial  measurements  of  cTnT  add
rognostic  information  in  the  management  of  chronic  HF
27].  However,  further  studies  are  required  to  ascertain  the
orrelation  between  long-term  variations  in  cTn  and  the
ong-term  incidence  of  fatal  and  non-fatal  adverse  events,
nd  conﬁrm  the  value  of  cTn  as  a  true  surrogate  marker  of
linical  outcomes.
iochemical markers and risk of chronic heart
ailure
n  ideal  biochemical  marker  should  be  applicable  to  patients
t  risk  of,  as  well  as  patients  suffering  from,  overt  chronic
F.  In  a  sample  of  nearly  29,000  apparently  healthy  American
omen  CRP  was  a  stronger  predictor  of  adverse  cardiovas-
ular  events  than  low-density  lipoprotein  cholesterol  [45].
n  the  Framingham  Heart  Study,  a  high  plasma  BNP  was  asso-
iated  with  an  increased  risk  of  progression  of  hypertension
n  men  [46]. And  in  the  Hisayama  Study,  slightly  elevated
T-proBNP  blood  concentrations  predicted  the  development
f  cardiovascular  disease  in  a  Japanese  general  population
47].  Recently,  minimally  elevated  concentrations  of  hs-
TnT  were  found  in  essential  hypertension  and  in  the  general
opulation  [48—51]. The  Atherosclerosis  Risk  in  Communi-
ies  study  found  that  a  hs-cTnT  concentration  >0.003  ng/ml
n  the  general  population  was  associated  with  an  elevated
isk  of  coronary  heart  disease,  HF,  and  death  [50]. In  the
ardiovascular  Health  Study,  baseline  and  subsequent  serial
easurements  of  hs-cTnT  over  2—3  years  of  follow-up  in
lder  adults  free  from  HF  were  signiﬁcantly  associated  with
he  later  development  of  HF  and  cardiovascular  deaths
51].
Whether  CRP,  BNP,  and  Hs-cTn  are  independent  and
eliable  surrogate  markers  of  long-term  adverse  clinical
vents  in  hypertensive  patients  or  in  the  general  population,
equires  further  studies.  In  a  recent  report,  the  combination
f  cTnI,  NT-proBNP,  CRP,  and  cystatin  C  improved  the  pre-
iction  of  death  from  cardiovascular  causes  in  elderly  men
52].
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onclusions
he  number  of  patients  suffering  from  HF  is  increasing
apidly  and,  on  a  global  scale,  the  majority  will  not  be
ared  for  by  highly  specialized  medical  centers.  This  sys-
ematic  review  will,  hopefully,  help  in  the  development  of
idely  applicable  management  strategies.  At  present,  BNP
nd  NT-proBNP  are  the  biochemical  markers,  which  make
he  greatest  contributions  in  the  (1)  risk  stratiﬁcation,  and
2)  diagnosis  of  HF  [16]. Several  other  emerging  biochemical
arkers  are  being  investigated,  and  study  protocols  based
n  multiple  markers  with  a  view  to  risk  stratify  and  monitor
r  target  therapy  warrant  consideration.
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